¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"reversed shunt"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mesocaval shunt operation
    ´ëÁ¤¸Æ°£¸·¼ÇÆ®¼ö¼ú
  • portacaval shunt
    ¹®¸Æ´ëÁ¤¸Æ¼ÇÆ®
  • portocaval shunt operation
    ¹®¸Æ´ëÁ¤¸Æ¼ÇÆ®¼ö¼ú
  • portosystemic shunt
    ¹®¸ÆÀü½Å¼ÇÆ®
  • peritoneovenous shunt
    º¹°­Á¤¸Æ¼ÇÆ®
  • right to left shunt
    ¿À¸¥¿ÞÂÊ¼ÇÆ®, ¿ìÁÂ¼ÇÆ®
  • splenorenal shunt
    Áö¶óÄáÆÏÁ¤¸Æ¼ÇÆ®, ºñÁ¤¸Æ½ÅÁ¤¸Æ¼ÇÆ®
  • subduro-peritoneal shunt
    ³ú°æ¸·ÇϺ¹°­¼ÇÆ®
  • shunt
    1. Áö¸§±æ, »çÀÕ±æ 2. ¼ÇÆ®, Áö¸§
  • shunt circuit
    ¼ÇƮȸ·Î
  • shunt effect
    Áö¸§±æÈ¿°ú, ¼ÇƮȿ°ú
  • shunt malfunction
    Áö¸§±æ±â´ÉºÒ·®, ¼ÇÆ®±â´ÉºÒ·®
  • shunt operation
    ¼ÇÆ®¼ö¼ú, Áö¸§¼ú
  • ventriculoatrial shunt
    ³ú½Ç½É¹æ¼ÇÆ®
  • ventriculoperitoneal shunt
    ³ú½Çº¹°­¼ÇÆ®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intracardiac shunt
    ½ÉÀå³»Áö¸§±æ
  • mesocaval shunt operation
    âÀÚ°£¸·´ëÁ¤¸Æ¿¬°á¼ú, Àå°£¸·Á¤¸Æ´ëÁ¤¸Æ¿¬°á¼ú
  • shunt malfunction
    Áö¸§±æ±â´ÉÀå¾Ö
  • shunt operation
    Áö¸§¼ú, ´Ü¶ô¼ö¼ú
  • paracellular shunt
    ¼¼Æ÷ÁÖÀ§Áö¸§±æ
  • portacaval shunt
    ¹®¸Æ´ëÁ¤¸ÆÁö¸§(¼ú), ¹®¸Æ´ëÁ¤¸Æ¿¬°á(¼ú)
  • portosystemic shunt
    ¹®¸ÆÀü½Å¼øÈ¯Áö¸§¼ú, ¹®¸ÆÀü½Å¼øÈ¯¿¬°á¼ú
  • renal shunt
    ÄáÆÏÇ÷·ùÁö¸§±æ, ½ÅÀåÇ÷·ùÁö¸§±æ
  • shunt
    Áö¸§±æ, Áö¸§¼ú, ´Ü¶ô
  • splenorenal shunt
    Áö¶óÄáÆÏÁ¤¸ÆÁö¸§¼ú, ºñ½ÅÁ¤¸Æ¿¬°á¼ú
  • subarachnoid ureteral shunt
    °Å¹Ì¸·¹Ø¿ä°üÁö¸§±æ, °Å¹Ì¸·¹Ø¿ä°üÁö¸§¼ú
  • subduro-atrial shunt
    ³ú°æ¸·¹Ø½É¹æÁö¸§¼ú
  • subduro-peritoneal shunt
    ³ú°æ¸·¹Ø¹è¾ÈÁö¸§¼ú
  • ventriculoatrial shunt
    ³ú½Ç½É¹æÁö¸§¼ú
  • ventriculocaval shunt
    ³ú½Ç»ó´ëÁ¤¸ÆÁö¸§¼ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reversed real image
    µµ¸³½Ç»ó(Óîí¡ãùßÒ).
  • reversed rhythm
    ¿ªÀü½É¹Ú(æ½ï®ãýÚÑ).
  • reversed rhythm
    ¿ªÀü½É¹Ú(æ½ï®ãýÚÑ)
  • arteriovenous shunt
    µ¿Á¤¸Æ¼ÇÆ®, µ¿Á¤¸Æ´Ü¶ô(¡­Ó­Õ©)
  • arteriovenous shunt
    µ¿Á¤¸Æ¼ÇÆ®, µ¿Á¤¸Æ´Ü¶ô(¡­´Ü¶ô).
  • bypass shunt
    ¿ìȸ·Î ´Ü¶ô(éæüÞÖØÓ­Õ©).
  • bypass shunt
    ȸ·Î°£µµ, ȸ·Î´Ü¶ô(ȸ·Î´Ü¶ô), ¿ìȸ·Î´Ü¶ô.
  • bypass shunt
    ¼øÈ­ [½Å¿Ü,ÈäºÎ]ȸ ·Î°£µµ, ȸ·Î´Ü¶ô(üßÖØÓ­Õ©), ¿ìȸ·Î´Ü¶ô.
  • cardiac shunt
    ½É´Ü¶ô(ãýÓ­Õ©)
  • hexose monophosphate shunt
    ÀÏÀλêÇí¼Ò½º¼ÇÆ®<--´Ü¶ô>
  • intracardiac shunt
    ½ÉÀå³»´Ü¶ô(¡­Ó­Õ©).
  • juxtamedullary shunt
    (¼öÁú)±ÙÁ¢ºÎ´Ü¶ô(âÐòõÐÎïÈݻӭթ).
  • left-to-right shunt
    Á¿ì¼ÇÆ®(ñ§éÓ¡­)
  • mesocaval shunt operation
    Àå°£¸·Á¤¸Æ´ëÁ¤¸Æ¹®ÇÕ¼ú(Àå°£¸·Á¤¸Æ´ëÁ¤¸Æ¹®ÇÕ¼ú).
  • portacaval shunt
    ¹®¸Æ´ëÁ¤¸Æ¹®ÇÕ(¼ú)(¹®¸Æ´ëÁ¤¸Æ¹®ÇÕ¼ú).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
VU shunt Ventriculo-Ureteral shunt
SP sacroposterior; sacrum to pubis; salivary progesterone; schizotypal personality; semi-private [room]...
RPHA reversed passive hemagglutination
RPHAMFCA reversed passive hemagglutination by miniature centrifugal fast analysis
PEEP Positive End-Expiratory Pressure
  ? Ix
    1. PaO2 < 60 mmHg, ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TIPS Transjugular Intrahepatic Portosystemic Shunt
TIPSS Transjugular Intrahepatic Portosystemic Stent Shunt
PSS porto-systemic shunt
ISRP Internal surface reversed-phase
RP HPLC Reversed phase high performance liquid chromatography
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
Rapoport-Luebering shunt Part of the glycolytic pathway characteristic of human erythrocytes in which 2,3-bisphosphoglycerate (2,3-P2Gri) is formed as an intermediate between 1,3-P2Gri and 3-phosphoglycerate; 2,3-P2Gri is an important regulator of the affinity of haemoglobin for oxygen.
(05 Mar 2000)
ventriculoperitoneal shunt <procedure> A surgical procedure to insert a communicating catheter to relieve intracranial pressure caused by hydrocephalus.
In this procedure the cerebrospinal fluid is shunted from the ventricles of the brain into the peritoneal cavity via a surgically implanted tube.
(27 Sep 1997)
Glenn shunt A means of palliating cyanotic heart disease by anastomosing the right pulmonary artery to the superior vena cava.
Synonym: cavopulmonary shunt, Glenn shunt.
(05 Mar 2000)
cavopulmonary shunt A means of palliating cyanotic heart disease by anastomosing the right pulmonary artery to the superior vena cava.
Synonym: cavopulmonary shunt, Glenn shunt.
(05 Mar 2000)
renal-splenic venous shunt Anastomosis of the splenic vein to the left renal vein, usually end-to-side, for control of portal hypertension.
Synonym: renal-splenic venous shunt.
(05 Mar 2000)
vp shunt <procedure> A surgical procedure to insert a communicating catheter to relieve intracranial pressure caused by hydrocephalus.
In this procedure the cerebrospinal fluid is shunted from the ventricles of the brain into the peritoneal cavity via a surgically implanted tube.
(27 Sep 1997)
pentose monophosphate shunt <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
mesocaval shunt Anastomosis of the side of the superior mesenteric vein to the proximal end of the divided inferior vena cava, for control of portal hypertension, h-shunt anastomosis of the inferior vena cava to the superior mesenteric vein, using a synthetic conduit or autologous vein.
(05 Mar 2000)
peritoneovenous shunt An operation for the continuous emptying of ascitic fluid into the venous system. Fluid removal is based on intraperitoneal and intrathoracic superior vena cava pressure differentials and is performed via a pressure-sensitive one-way valve connected to a tube traversing the subcutaneous tissue of the chest wall to the neck where it enters the internal jugular vein and terminates in the superior vena cava. It is used in the treatment of intractable ascites.
(12 Dec 1998)
right-to-left shunt The passage of blood from the right side of the heart into the left (as through a septal defect), or from the pulmonary artery into the aorta (as through a patent ductus arteriosus); such a shunt can occur only when the pressure on the right side exceeds that in the left, as in advanced pulmonic stenosis, or when the pulmonary artery pressure exceeds aortic pressure, as in one form of Eisenmenger's syndrome or in tricuspid atresia.
(05 Mar 2000)
Warburg-Dickens-Horecker shunt <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
Warburg-Lipmann-Dickens-Horecker shunt <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
Warren shunt Anastomosis of the splenic end of the divided splenic vein to the left renal vein.
Synonym: distal splenorenal shunt.
(05 Mar 2000)
Waterston shunt Creation of a narrow (about 3 mm) opening between the ascending aorta and the subjacent right pulmonary artery to increase pulmonary circulation in cyanotic heart disease with decreased pulmonary flow.
(05 Mar 2000)
complications of ventriculo-peritoneal shunt <radiology> Kinking, interruption, exit from peritoneal cavity with growth, through processus vaginalis to scrotum, CSFoma, mass effect exhibited on bowel gas pattern with malfunctioning shunt, lack of movement of shunt tip with positional or temporal change, perforation of hollow viscus (e.g., bowel or bladder)
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á